Cymbalta, Ariclaim(duloxetine)
Cymbalta, Drizalma, Duloxetine, Yentreve (duloxetine) is a small molecule pharmaceutical. Duloxetine was first approved as Cymbalta on 2004-08-03. It is used to treat anxiety disorders, diabetic neuropathies, major depressive disorder, and musculoskeletal pain in the USA. It has been approved in Europe to treat anxiety disorders, diabetes mellitus, diabetic neuropathies, major depressive disorder, and neuralgia amongst others. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cymbalta, Drizalma, Duloxetine (discontinued: Duloxetine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Duloxetine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CYMBALTA | Eli Lilly | N-021427 RX | 2004-08-03 | 3 products, RLD, RS |
| DRIZALMA SPRINKLE | Sun Pharmaceutical Industries | N-212516 RX | 2019-07-19 | 4 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cymbalta | New Drug Application | 2024-11-06 |
| drizalma sprinkle | New Drug Application | 2024-05-14 |
| duloxetine | ANDA | 2025-01-08 |
| duloxetine delayed-release | ANDA | 2017-04-21 |
| duloxetine duloxetine | ANDA | 2024-04-08 |
| duloxetine duloxetine hydrochloride | ANDA | 2017-08-14 |
| duloxetine hcl | ANDA | 2024-12-31 |
| duloxetine hydrochloride | ANDA | 2024-12-18 |
| duloxicaine | unapproved drug other | 2023-01-25 |
| na | ANDA | 2024-12-19 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DULOXETINE HYDROCHLORIDE, CYMBALTA, LILLY | |||
| 2023-04-20 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
418 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stress urinary incontinence | D014550 | HP_0010992 | — | — | 2 | 8 | 2 | — | 12 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 3 | 7 | — | 10 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | — | 1 | 7 | 2 | — | 10 |
| Enuresis | D004775 | — | R32 | — | 1 | 7 | 2 | — | 10 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 3 | 6 | — | 9 |
| Depression | D003863 | — | F33.9 | — | — | 3 | 4 | — | 7 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | 2 | 3 | — | 5 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | 1 | 3 | 1 | 5 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | 3 | 1 | — | 4 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | 3 | 1 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 6 | — | — | 6 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | 1 | 2 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | 1 | — | — | 1 |
| Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Duloxetine |
| INN | duloxetine |
| Description | (S)-duloxetine is a duloxetine. It is an enantiomer of a (R)-duloxetine. |
| Classification | Small molecule |
| Drug class | antidepressants (fluoxetine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNCC[C@H](Oc1cccc2ccccc12)c1cccs1 |
Identifiers
| PDB | — |
| CAS-ID | 116539-59-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1175 |
| ChEBI ID | 36795 |
| PubChem CID | 60835 |
| DrugBank | DB00476 |
| UNII ID | O5TNM5N07U (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cymbalta – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Duloxetine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,979 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cymbalta, Drizalma sprinkle, Duloxetine, Duloxetine delayed-release, Duloxetine duloxetine, Duloxetine duloxetine hydrochloride, Duloxetine hcl, Duloxetine hydrochloride, Duloxicaine, Na
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
79,490 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use